Here are the 10-K annual reports from Silo Pharma, Inc. (SILO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SILO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SILO filings page.
Silo Pharma, Inc. filed its annual report describing a developmental-stage biopharmaceutical and cryptocurrency company focused on CNS and pain disorders. The pipeline includes SPC-15, an intranasal PTSD and anxiety treatment advancing toward an IND, SP-26 ketamine implants for fibromyalgia, SPC-14 for Alzheimer’s disease and SPU-16 for multiple sclerosis.
Silo licenses key IP from Columbia University, the University of Maryland, Baltimore and Medspray for nasal delivery technology, and reports five issued patents with 20 pending applications. In 2025 it added a cryptocurrency treasury strategy, holding crypto assets of $221,817 and staking $98,584 to earn yield.
The company highlights significant regulatory and clinical risks around psychedelic-based therapies, controlled substance compliance and financing needs. As of March 27, 2026, it had 14,166,593 common shares outstanding, three full-time employees and a Board-authorized stock repurchase program of up to $1 million through December 31, 2026.